HAYWARD, Calif.--(BUSINESS WIRE)--May 9, 2006--Guava Technologies, Inc., a leading developer of cost-effective and accessible cell-analysis systems for life science research, drug discovery, development and clinical diagnostics, today announced that Guava has received 510(k) clearance from the U.S. Food and Drug Administration for the Guava® EZCD4 System, which includes the EZCD4 Assay, the PCA Instrument and CytoSoft v2.3 Software, incorporating three modules (EZCD4, Guava Check and Clean and Shutdown). The EZCD4 System is intended to identify and quantify absolute counts of CD4+ T-Lymphocytes in EDTA whole blood. Utilizing Guava’s easy-to-use and cost-effective Microcapillary Cytometry Technology, the Guava EZCD4 System is intended for the ongoing monitoring of patients with documented diagnosis of an immunodeficiency disease.
